Romiplostim | 合法藥品大搜索

2008年美國食品暨藥物管理局（FDA）核准兩種血小板生成素受體致效劑（TPO receptor agonist）：romiplostim 與eltrombopag，其中romiplostim（NPlate）則是 ... Read More

Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production. Read More

由 D Hubulashvili 著作 · 2009 · 被引用 12 次 — Romiplostim is an Fc-peptide fusion protein (peptibody) that stimulates intra-cellular transcriptional pathways, which results in increased platelet production by ... Read More

由 CE Neunert 著作 · 2019 · 被引用 12 次 — In December 2018, the US FDA approved romiplostim for use in pediatric patients ≥1 year of age with ITP of >6 months' duration and insufficient ... Read More

Romiplostim is a fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Read More

Romiplostim is used for the treatment of thrombocytopenia (low platelets) in patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) who have ... Read More

2021年2月22日 — Romiplostim, a member of the TPO mimetic class, is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional ... Read More

由 MM Gilbert 著作 · 2020 — Romiplostim is a peptide-antibody fusion product which consists of two dimerized peptides conjugated to the heavy chain of IgG1 (Figure 2). Read More

由 DJ Kuter 著作 · 2011 · 被引用 27 次 — With few adverse effects, romiplostim is effective in raising the platelet count in over 80% of ITP patients, allowing them to discontinue other therapies, reduce the ... Read More